In more than 70 countries, Médecins Sans Frontières provides medical humanitarian assistance to save lives and ease the suffering of people in crisis situations.
We set up the MSF Access Campaign in 1999 to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.
Based in Paris, CRASH conducts and directs studies and analysis of MSF actions. They participate in internal training sessions and assessment missions in the field.
Based in Geneva, UREPH (or Research Unit) aims to improve the way MSF projects are implemented in the field and to participate in critical thinking on humanitarian and medical action.
Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.
This logistical and supply centre in Brussels provides storage of and delivers medical equipment, logistics and drugs for international purchases for MSF missions.
This supply and logistics centre in Bordeaux, France, provides warehousing and delivery of medical equipment, logistics and drugs for international purchases for MSF missions.
This logistical centre in Amsterdam purchases, tests, and stores equipment including vehicles, communications material, power supplies, water-processing facilities and nutritional supplements.
BRAMU specialises in neglected tropical diseases, such as dengue and Chagas, and other infectious diseases. This medical unit is based in Rio de Janeiro, Brazil.
Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.
Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.
Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.
MSF works with LGBTQI+ populations in many settings over the last 25-30 years. LGBTQI+ people face healthcare disparities with limited access to care and higher disease rates than the general population.
The Luxembourg Operational Research (LuxOR) unit coordinates field research projects and operational research training, and provides support for documentation activities and routine data collection.
The MSF Paediatric Days is an event for paediatric field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field.
The MSF Foundation aims to create a fertile arena for logistics and medical knowledge-sharing to meet the needs of MSF and the humanitarian sector as a whole.
A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.
Noma is a preventable and treatable neglected disease, but 90 per cent of people will die within the first two weeks of infection if they do not receive treatment.
Coronaviruses are a large family of viruses, most of which are harmless for humans. However, some types can cause severe lung infections.
MSF is currently responding to a worldwide coronavirus pandemic, COVID-19. We have previously responded to other outbreaks of serious coronavirus, including Severe Acute Respiratory Syndrome (SARS).
While four types of coronavirus are known to cause colds, SARS and Middle East Respiratory Syndrome (MERS) can cause severe lung infections, and can be fatal. A new coronavirus known as SARS-CoV-2, because of its similarities to the virus that causes SARS, causes the new disease COVID-19.
This new coronavirus seems to target cells in the lungs, and possibly other cells in the respiratory system too. Cells infected by the virus will produce more virus particles, which can then spread to other people, for instance by coughing. COVID-19 will be a mild respiratory illness for the vast majority of people but it has a higher rate of quite severe complications for vulnerable people (elderly and people with comorbidities), than other viruses such as flu.
Five things to know about the coronavirus pandemic
We’ve never seen a global outbreak like the new coronavirus disease, or COVID-19. It threatens to overwhelm health systems and health workers everywhere unless we all take immediate action. Here are five things to know about what makes this pandemic so dangerous, and what can be done to slow the spread of the virus. Simple measures can help flatten the curve of the epidemic, including physical distancing and proper hand washing.
Coronavirus COVID-19 pandemic
Providing materials, engaging communities in the COVID-19 coronavirus outbreak
Project Update14 Feb 2020
Coronavirus COVID-19 pandemic
MSF update on COVID-19 coronavirus outbreak
Project Update14 Feb 2020
China
MSF opens program in China to help stop spread of SARS
Press Release23 May 2003
Hong Kong
SARS protection supplies donated to Hong Kong hospital authority
Project Update10 Apr 2003
Vietnam
MSF expands SARS intervention in Vietnam
Press Release2 Apr 2003
You might also like to read about
In Focus
Coronavirus COVID-19 pandemic
Médecins Sans Frontières' (MSF) update on the coronavirus disease COVID-19 pandemic.
Crisis Settings
Epidemics and pandemics
Millions of people still die each year from infectious diseases that are preventable or can be treated.
Crisis Settings
Access to medicines
Unaffordable, unavailable, not adapted - people around the world face these challenges in accessing lifesaving medicines.
